Prostaglandin F2-alpha (PGF2α) in Vitiligo

Vitiligo Clinical Trial

Official title:

Study of the Cutaneous Expression of Prostaglandin F2-alpha (PGF2α) in Vitiligo Patients: a Case-control Study.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03755830
• Other study ID #: Dermatology 10
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 2018
• Est. completion date: July 2019

Study information

• Verified date: November 2018
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

study the cutaneous expression of PGF2α in vitiligo patients and compare it with normal control subjects.

Description:

Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: July 2019
• Est. primary completion date: July 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with non-segmental vitiligo.

• Both sexes.

• Age < 18 years old.

• New cases or cases not receiving any medications for at least 3 months ago.

Exclusion Criteria:

• Age: Patients < 18 years.

• Segmental or universal vitiligo.

• Pregnant and lactating females.

Related Conditions & MeSH terms

• Vitiligo

Intervention

Other:
• Skin biopsy
Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of tissue levels of PGF2a in vitiligo patients and compare them with healthy controls.	Measurement of tissue levels of PGF2a in vitiligo patients and compare them with healthy controls to study and verify the hypothesis of involvement of PGF2a in the pathogenesis of vitiligo.• Skin biopsy for assessment of tissue levels of the PGF2a will be taken from both lesional and non lesional skin of patients of vitiligo and from normal skin of healthy controls. All skin biopsies are from non-sun exposed sites.	6 months